{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:06:26Z","timestamp":1787061986760,"version":"build-2736575974"},"reference-count":14,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Technology"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Clinicians often use parenteral lead-in regimens prior to direct oral anticoagulants (DOACs) for venous thromboembolism (VTE) in hospitalized patients due to shorter half-life and the ability to use laboratory monitoring.\n                    <jats:bold>Objective:<\/jats:bold>\n                    This study evaluates the effectiveness and safety of different apixaban lead-in durations for hospitalized adults with newly diagnosed VTE.\n                    <jats:bold>Methods:<\/jats:bold>\n                    Retrospective review of patients with one of the following lead-in regimens: (1) parenteral anticoagulation \u2265 48 hours with abbreviated course of apixaban lead-in, (2) parenteral anticoagulation \u2265 48 hours with full apixaban lead-in, or (3) no parenteral anticoagulation with full apixaban lead-in. All followed by maintenance apixaban for at least 6 months. Primary outcomes were incidences of recurrent VTE (rVTE) or bleeding events, in accordance with International Society on Thrombosis and Hemostasis (ISTH) definitions, within 6 months of the index visit. Data are presented descriptively and univariate analyses between groups performed.\n                    <jats:bold>Results:<\/jats:bold>\n                    Sixty-eight patients were included; rVTE (all deep vein thrombosis (DVT)) occurred in 2 patients (2.9%) and bleeding events (all clinically relevant non-major bleeding) occurred in 3 patients (4.4%) overall. There were no differences between groups; one patient in the parenteral group had full lead-in and one patient in the full-lead apixaban group had rVTE. One patient in the parenteral with full lead-in and 2 patients in the full lead-in apixaban group had a bleeding event (\n                    <jats:italic>P<\/jats:italic>\n                    = 0.99). Mean time to rVTE or bleeding event was 46 and 158 days, respectively.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Similar safety and effectiveness were noted between the 3 apixaban lead-in regimens. These findings suggest that all 3 regimens provide similar outcomes, warranting further investigation to optimize lead-in strategies.\n                  <\/jats:p>","DOI":"10.1177\/87551225251326436","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T06:56:06Z","timestamp":1742194566000},"page":"108-115","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparing the Safety and Effectiveness of Apixaban Lead-In Dosing Strategies in Hospitalized Adults With Venous Thromboembolism"],"prefix":"10.1177","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9914-6036","authenticated-orcid":false,"given":"Juliana","family":"Spencer","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3341-5407","authenticated-orcid":false,"given":"Tanner","family":"Buchanan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7310-6880","authenticated-orcid":false,"given":"Samantha","family":"Heacock","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Heacock","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian","family":"Brennan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hutchinson","sequence":"additional","affiliation":[{"name":"Wegmans School of Pharmacy, St John Fisher University, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Radcliffe","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"CDC. Data and statistics on venous thromboembolism. Centers for Disease Control and Prevention. Published 2024. Accessed October 20 2024. https:\/\/www.cdc.gov\/blood-clots\/data-research\/facts-stats\/index.html"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2013.08.003"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.6.809"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.120.017559"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010199"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1302507"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1007903"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1306638"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0906598"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.2147\/ijgm.s392505"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13140"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-017-1473-5"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-022-02641-5"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/jac5.1353"}],"container-title":["Journal of Pharmacy Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225251326436","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/87551225251326436","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225251326436","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:33:09Z","timestamp":1777602789000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/87551225251326436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1177\/87551225251326436"],"URL":"https:\/\/doi.org\/10.1177\/87551225251326436","relation":{},"ISSN":["8755-1225","1549-4810"],"issn-type":[{"value":"8755-1225","type":"print"},{"value":"1549-4810","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]}}}